Vapreotide debipharm

IDrugs

Volumn 3, Issue 11, 2000, Pages 1358-1372

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747847571     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (249)

1. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Liebow C, Reilly C, Serrano M, Schally AV PROC NATL ACAD SCI U S A 1989 86 6 2003-2007
2. RC-160. DRUGS FUTURE 1989 14 11 1052-1055
3. Evaluation of receptors for somatostatin in various tumors using different analogs. Srkalovic G, Cai RZ, Schally AV J CLIN ENDOCRINOL METAB 1990 70 3 661
4. Effect of somatostatin analogs on gastric acid secretion in dogs and rats. Schally AV, Colaluca J, Paulson D, Carter WH, Neitzschm an HR, Lafaye H, Cai R Z INT J PEPT PROTEIN RES 1990 36 3 267-274
5. Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies. Klijn JGM, Setyono Han B, Bakker GH, Van Der Burg-MEL, Bontenbal M, Peters HA, Sieuwerts AM, Berns PMJJ, Foekens JA J STEROID BIOCHEM MOL BIOL 1990 37 6 1089-1095
6. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J J SURG RES 1991 50 3 245-251
7. Somatostatin analogues in cancerology. Thomas F, Parmar H, Prevost G, Kuhn JM, Bejot JL, Moreau JP, Bogden A BULL CANCER 1991 78 8 693-707
8. Somatostatin receptors in human neuroblastoma cells. Maggi M, Baldi E, Lanzillotti R, Francheschelli F, Finetti G, Camboni MG, Serio M, Thiele CJ CHRON DERMATOL 1992 2 438-439
9. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Weckbecker G, Tolcsvai L, Liu R, Bruns C METABOLISM 1992 41 99-103
10. Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence. Liebow C, Crean DH, Schally AV, Mang TS PROC NATL ACAD SCI U S A 1993 90 1897-1901
11. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Banks WA, Schally AV, Barrera CM, Fasold MB, Durham DA, Csemus VJ, Groot K, Kastin AJ PROC NATL ACAD SCI U S A 1990 87 6762-6766
12. Effects of somatostatin-14 and its analogs on the (Ca,Mg)ATPase in the rat anterior pituitary. Lachowicz A, Pawlikowski M BIOCHEM BIOPHYS RES COMMUN 1991 178 3 1492-1497
13. Inhibitory effect of bombesin/gastrin peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Szepeshazi K, Schally AV, Cai RZ, Radulovic S, Milovanovic S, Szoke B CANCER RES 1991 51 21 5980-5986
14. Hormonal therpay of pancreatic carcinoma: rationale and perspectives. Perilli D, Mansi C, Savarino V, Celle G INT J PANCREATOL 1993 13 3 159-168
15. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV INT J CANCER 1994 57 4 574-580
16. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J, Reile H, Halmos G, Groot K, Schally AV CANCER RES 1994 54 1 169-174
17. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Pinski J, Schally AV, Halmos G, Szepeshazi K INT J CANCER 1993 55 6 963-967
18. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Pinski J, Halmos G, Schally AV CANCER LETT 1993 71 1-3 189-196
19. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Radulovic S, Comaru Schally AM, Milovanovic S, Schally AV PANCREAS 1993 8 1 88-97
20. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human gliobiastomas in vitro and in vivo. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K CANCER RES 1994 54 5895-5901
21. [New drug therapies during the French workshops]. Les therapeutiques nouvelles aux journées francophones. MED CHIR DIG 1994 23 4 262-263
22. Relative potencies of the somatostatin analogs octreotide, BIM-23014 and RC-160 on the inhibition of hormone release by cultured human endocrine tumour cells and normal rat anterior pituitary cells. Hofland LJ, Van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW ENDOCRINOLOGY 1994 134 301-306
23. Receptors for somatostatin and somastostatin analogs in breast tumors. Prevost G, Hosford D, Thomas F ANN NY ACAD SCI 1994 733 147-154
24. Neuroendocrine differentiation in prostatic carcinoma: Recent findings and new concepts. Sant'Agnese PA Di CANCER 1995 75 7 1850-1859
25. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Hofland LJ, Visser Wisselaar HA, Lamberts SWJ BIOCHEM PHARMACOL 1995 50 3 287
26. Localization and pharmacological characterization of somatostatin sst2 sites in the rat cerebellum. Piwko C, Thoss VS, Hoyer D NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1995 352 6 607-613
27. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Emons G, Schally AV HUM REPROD 1994 9 7 1364-1379
28. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Bryne K, Cai RZ BR J CANCER 1994 70 5 886-892
29. Apoptosis in pancreatic cancers of hamsters. Szepeshazi K, Schally AV, Halmos G INT J PANCREATOL 1994 16 2 - 3 282-287
30. Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer. Schally AV, Szepeshazi K, Qin Y, Halmos G, Ertl T, Groot K, Cai R-Z, Liebow C, Poston GJ INT J PANCREATOL 1994 16 2-3 246-249
31. Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Schally AV, Comaru-Schally AM, Gonzalez-Barcena D BIOMED PHARMACOTHER 1992 46 10 465-471
32. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and the somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Yano T, Pinski J, Szepeshazi K, Milanovic SR, Groot K, Schally AV PROSTATE 1992 20 4 297-310
33. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somastatin, or a combination. Szepeshazi K, Milanovic S, Lapis K, Groot K, Schally AV BREAST CANCER RES TREAT 1992 21 3 181-192
34. Differential effects of LHRH and somatostatin analogs on human breast cancer. Brower ST, Schally AV, Redding TW, Hollander VP J SURG RES 1992 52 1 6-14
35. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Szepeshazi K, Lapis K, Schally AV INT J CANCER 1991 49 2 260-266
36. Radiolabelled somatostatin analogue scintigraphy in oncology. O'Byrne KJ, Camey DN ANTI CANCER DRUGS 1996 7 Suppl 1 33-44
37. Somatostatin receptors: Types and classification in the pituitary. James RA, Weightman DR ENDOCRINOLOGIST 1995 5 1 55-60
38. Somatostatin receptor expression in lung cancer. O'Byrne KJ, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, Carney DN EUR J CANCER 1994 30 11 1682-1687
39. 111In-DTPA-D-Phe1]Octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Tiensuu Janson E, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K EUR J ENDOCRINOL 1994 131 6 577-581
40. Gastrin antagonists and gastrointestinal tumours. Watson SA EXP OPIN INVEST DRUGS 1995 4 12 1253-1266
41. Somatostatin receptors in the Rhesus monkey brain: Localization and pharmacological characterization. Thoss VS, Piwko C, Hoyer D NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1996 353 6 648-660
42. The somatostatin receptor family. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB LIFE SCI 1995 57 13 1249-1265
43. Angiogenesis inhibiton as a drug target for disease: an update. Seed MP EXP OPIN INVEST DRUGS 1996 5 12 1617-1637
44. Review article: anti-diarrhoeal pharmacology and therapeutics. Schiller LR ALIMENT PHARMACOL THER 1995 9 2 87-106
45. Intervention - High-priority research approaches for prevention and for intervening in early pancreatic cancer. Comaru Schally AM INT J PANCREATOL 1994 16 2-3 307-309
46. The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastrointestinal tumors. Eriksson B, Jansen ET, Bax NDS, Mignon M, Morant R, Opolon P, Rougier P, Oberg KE DIGESTION 1996 57 177-180
47. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. Forloni G, Lucca E, Angeretti N, Chiesa R, Vezzani A J NEUROCHEM 1997 68 1 319-327
48. Drug development pipeline: vapreotide. Debiopharm SA COMPANY COMMUNICATION 1997 March 06
49. Hormones, vitamins, and growth factors in cancer treatment and prevention: A critical appraisal. Lupulescu AP CANCER 1996 78 11 2264-2280
50. Stabilization of Octastatin, a somatostatin analogue: comparative accelerated stability studies of two formulations for freeze-dried products. Barthomeuf C, Pourrat H, Pourrat A, Ibrahim H, Cottier PE PHARM ACTA HELV 1996 71 2 161-166
51. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Buscail L, Saint Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C CANCER RES 1996 56 8 1823-1827
52. Stabilization of Octastatin, a somatostatin analogue. Preparation of freeze-dried products for parenteral injection. Pourrat H, Barthomeuf C, Pourrat A, Cottier PE, Ibrahim H BIOL PHARM BULL 1995 18 5 766-771
53. In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin. Betoin F, Advenier C, Fardin V, Wilcox G, Lavarenne J, Eschalier A EUR J PHARMACOL 1995 279 2-3 241-249
54. Molecular pharmacology of somatostatin receptors. Viollet C, Prevost G, Maubert E, Faivre Bauman A, Gardette R, Kordon C, Loudes C, Slama A, Epelbaum J FUNDAM CLIN PHARMACOL 1995 9 2 107-113
55. Seven-day antinociceptive effect of a sustained release vapreotide formulation. Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J NEUROREPORT 1994 5 5 642-644
56. Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV AIDS 1992 6 7 715-718
57. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Janson ET, Gobi A, Kalkner KM, Oberg K CANCER RES 1996 56 11 2561-2565
58. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Pinski J, Schally AV, Halmos G, Szepeshazi K, Grool K INT J CANCER 1996 65 6 870-874
59. Vapreotide labeled with Tc-99m for imaging tumors: Preparation and preliminary evaluation. Thakur ML, Kolan HR, Rifat S, Li J, Rux A, John E, Halmos G, Schally AV INT J ONCOL 1996 9 3 445-451
60. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A GYNECOL ONCOL 1996 61 3 345-348
61. Studies on radiolabeled somatostatin analogues in rats and in patients. Breeman WAP, Bakker WH, De Jong M, Hofland LJ, Kwekkeboom DJ, Kooij PP, Visser TJ, Krenning EP QUART J NUCL MED 1996 40 3 209-220
62. Differential desensitization of the actions of the somatostatin analogue vapreotide in healthy volunteers. Drewe J, Ritz M, Ziel A, Schneider J, Beglinger C NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1996 353 4 Suppl R163
63. Somatostatin analogs: Future directions. Lamberts SWJ, Van der Lely AJ, De Herder WW, Hofland LJ METABOLISM 1996 45 8 Suppl 104-106
64. Comparison of analgesic and antiinflammatory properties of vapreotide and piroxicam chronically administered in polyarthritic rats. Dubray C, Alloui A, Dubost JJ, Sauvezie B, Eschalier A, Lavarenne J FUNDAM CLIN PHARMACOL 1996 10 1 78
65. Effector coupling of somatostatin receptor subtypes on human endocrine tumors. Kubota A, Yamada Y, Kagimoto S, Seino S, Seino Y METABOLISM 1996 45 8 Suppl 42-45
66. Molecular biology of somatostatin receptor subtypes. Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson L A, Srikant CB METABOLISM 1996 45 8 Suppl 31-38
67. Therapeutic potential of octreotide in the treatment of liver metastases. Davies N, Cooke TG, Jenkins SA ANTI CANCER DRUGS 1996 7 Suppl 1 23-31
68. Receptor-specific somatostatin analogs: Correlations with biological activity. Coy DH, Taylor JE METABOLISM 1996 45 8 Suppl 21-23
69. Binding properties of somatostatin receptor subtypes. Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G METABOLISM 1996 45 8 Suppl 1 17-20
70. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Buscail L, Esteve J P, Saint Laurent N, Bertrand V, Reisine T, O'Carroll A M, Bell GI, Schally AV, Vaysse N, Susini C PROC NATL ACAD SCI USA 1995 92 5 1580-1584
71. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Qin Y, Ertl T, Groot K, Horvath J, Cai RZ, Schally AV INT J CANCER 1995 60 5 694-700
72. Hepatocyte growth factor is a potent mitogen for normal human pancreas cells in vitro. Vila MR, Nakamura T, Real FX LAB INVEST 1995 73 3 409-418
73. Molecular pharmacology of somatostatin receptors. Hoyer D, Lubbert H, Bruns C NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1994 350 5 441-453
74. Advances in Oncology, Second World Congress, Vouliagmeni, Greece. Blasecki JW IDDB MEETING REPORT 1997 October 16-18
75. Vapreotide (RC160) in hormonorefractory (Hr) prostate adenocarcinoma (PC): a phase II study. Di Palma M, Bensadoun H, Benoit G, Oudard S, Teillac P, Prapotnich D, Besseghir K, Misset JL PROC AM ASSOC CANCER RES 1998 39 New Orleans Abs 3431
76. Therapeutic applications of somatostatin analogues Osapay G, Osapay K EXP OPIN THER PAT 1998 8 7 855-870
77. Evidence for a role for bulbospinal pathways in the spinal antinociceptive effect of systemically administered vapreotide in normal rats Berger V, Alloui A, Kemeny JL, Dubray C, Eschalier A, Lavarenne J Z LARMBEKAMPF 1998 12 2 200-204
78. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csemus V, Kovacs M, Koppan M, Szepeshazi K, Kahan Z PROC NATL ACAD SCI U S A 1998 95 4 1794-1799
79. Effects of new bombesin antagonists given singly or in combination with a somatostatin analog on nitrosamine-induced pancreatic cancers in hamsters. Szepeshazi K, Schally AV, Cai RZ, Halmos G, Groot K INT J ONCOL 1996 9 3 397-403
80. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Milovanovic SR, Radulovic S, Groot K, Schally AV PROSTATE 1992 20 4 269-280
81. Hormonal modulation of photofrin-R uptake. Sindoni FT, Mang TS, Crean DH, Liebow C LASERS SURG MED 1992 Suppl 4 53-54
82. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Radulovic S, Miller G, Schally AV CANCER RES 1991 51 21 6006-6009
83. sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. Bousquet C, Delesque N, Lopez F, Saint Laurent N, Estève JP, Bedecs K, Buscail L, Vaysse N, Susini C J BIOL CHEM 1998 273 12 7099-7106
84. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P CANCER 1998 82 5 909-917
85. Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue. Rothen Weinhold A, Besseghir K, De Zelicourt Y, Gurny R J CONTROL RELEASE 1998 52 1-2 205-213
86. 111In-DTPA0]octreotide. Breeman WAP, van Hagen PM, Kwekkeboom DJ, Visser TJ, Krenning EP EUR J NUCL MED 1998 25 2 182-186
87. Mechanisms of antineoplastic action of somatostatin analogs. Pollak MN, Schally AV PROC SOC EXP BIOL MED 1998 217 2 143-152
88. Somatostatin analog RC-160, LH-RH antagonist cetrorelix and bombesin antagonist RC-3940-II inhibit growth of Caki-I human renal carcinoma. Jungwirth A, Frick J, Scahlly AV, Halmos G, Groot K, Szepesnazi K, Pinski J J UROL 1998 159 5 Suppl 189
89. Hemodynamic effects of vapreotide, a new somatostatin analogue, in patients with cirrhosis. Gadano A, Vachiery F, Denie C, Trombino C, Moreau R, Yong S, Hillaire S, Valla D, Schneider P, Lebrec D J HEPATOL 1998 23 Suppl 159
90. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ J MED CHEM 1999 42 8 1341-1347
91. Somatostatin antagonists. Biomeasure Inc EXP OPIN THER PAT 1999 9 5 657-660
92. Neuronal nitric oxide synthase: a new susbtrate for SHP-1 required for SST2 somatostatin receptor-mediated cell growth inhibition. Lopez F, Ferjoux G, SaintLaurent N, Cordelier P, Estève JPP, Vaysse N, Buscail N, Susini C GASTROENTEROLOGY 1999 Orlando May 16-19 Abs 3758
93. TT-232, a novel heptapeptide somatostatin analog, as a potent anti-inflammatory and anti-nociceptive compound. Helyes Zs, Pinter E, Oroszi G, Keri Gy, Szolcsanyi J FUNDAM CLIN PHARMACOL 1999 13 Suppl 1 PW13
94. Novel lipoamino acid- and liposaccharide-based system for peptide delivery: application for oral administration of tumor-selective somatostatin analogues. Toth I, Malkinson JP, Flinn NS, Drouillat B, Horvath A, Erchegyi J, Idei M, Venetianer A, Artursson P, Lazorova L, Szende B, Keri G J MED CHEM 1999 42 19 4010-4013
95. Biopartnering - Debiopharm. ANN BIOPARTNERING EUROPE MEET 1999 October 18-19
96. Palatin recevies SBIR development grant for improved tumor diagnostic agent. Palatin Technologies Inc PRESS RELEASE 1996 October 09
97. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. Pagès P, Benali N, Saint Laurent N, Estève JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L J BIOL CHEM 1999 274 21 15186-15193
98. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, Woodhull J, Talbot DC, Schally AV, Harris AL BR J CANCER 1999 79 9-10 1413-1418
99. Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability. Dasgupta P, Singh AT, Mukherjee R PHARM RES 1999 16 7 1047-1053
100. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Decristoforo C, Mather SJ EUR J NUCL MED 1999 26 8 869-876
101. Somatostatin receptor ligands and their use in the treatment of endocrine disorders. Janson ET, Oberg K CURR PHARM DESIGN 1999 5 9 693-705
102. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, Schally AV, Taketani Y AM J OBSTET GYNECOL 1999 181 3 583-590
103. Acute hemodynamic effects of vapreotide in cirrhotic rats. Oberti F, Veal N, Moal F, Besseghir K, Cales P NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1999 360 5 488-499
104. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Siehler S, Seuwen K, Hoyer D NAUNYN SCHMIEDEBERG'S ARCH PHARMACOL 1999 360 5 488-499
105. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, Vadillo Buenfil M, Rodriguez Martin E J CANCER RES CLIN ONCOL 1999 125 8-9 444-452
106. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Decristoforo C, Mather SJ BIOCONJUG CHEM 1999 10 3 431-438
107. Early administration of vapreotide, a new somatostatin analogue, and endoscopic therapy for acute portal hypertensive bleeding in patients with cirrhosis. A randomized trial. French Club For The Study of PHT, Cales P HEPATOLOGY 1999 30 4 PART 2 419A
108. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Decristoforo C, Mather SJ NUCL MED BIOL 1999 26 4 389-396
109. Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Dasgupta P, Singh AT, Mukherjee R BIOCHEM BIOPHYS RES COMMUN 1999 259 2 379-384
110. Importance of the test medium for the release kinetics of a somatostatin analogue from poly(D,L-lactide-co-glycolide) microspheres. Blanco Prieto MJ, Besseghir K, Orsolini P, Heimgartner F, Deuschel C, Merkle HP, Nam Tran H, Gander B INT J PHARM 1999 184 2 243-250
111. Stability studies of a somatostatin analogue in biodegradable implants. Rothen Weinhold A, Besseghir K, Vuaridel E, Sublet E, Oudry N, Gurny R INT J PHARM 1999 178 2 213-221
112. The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects. Ritz MA, Drewe J, Ziel A, Hildebrand P, Schneider P, Lahlou N, Beglinger C BR J CLIN PHARMACOL 1999 47 2 195-201
113. Injection-molding versus extrusion as manufacturing technique for the preparation of biodegradable implants. Rothen Weinhold A, Besseghir K, Vuaridel E, Sublet E, Oudry N, Kubel F, Gurny R EUR J PHARM BIOPHARM 1999 48 2 113-121
114. Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Pelley RJ, Bukowski RM CURR OPIN ONCOL 1999 11 1 32-37
115. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Eriksson B, Oberg K ANN ONCOL 1999 10 2 S31-2 S38
116. Somatostatin and octreotide: Physiological background and pharmacological application. Beglinger C, Drewe J DIGESTION 1999 60 Suppl 2 2-8
117. Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. Scarpignato C, Pelosini I DIGESTION 1999 60 Suppl 3 1-16
118. Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment Oberg K ANN ONCOL 1999 10 Suppl 2 S3-S8
119. Somatostatin decreases somatostatin messenger ribonucleic acid levels in the rat periventricular nucleus. Aguila MC PEPTIDES 1998 19 9 1573-1579
120. 188Re- and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre- and postconjugate labeling. Guhlke S, Schaffland A, Zamora PO, Sartor J, Diekmann D, Bender H, Knapp FF, Biersack HJ NUCL MED BIOL 1998 25 7 621-631
121. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS J SURG RES 1993 55 4 446-453
122. Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: A study with magnetic resonance imaging. Qin Y, Van Cauter ENM, Osteaux M, Schally AV, Willems G CANCER RES 1992 52 21 6025-6030
123. Vapreotide. BMY-41606. RC-160. DRUGS FUTURE 1992 17 11 1069-1070
124. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Qin Y, Schally AV, Willems G INT J CANCER 1992 52 5 791-796
125. Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas. Banks WA, Kastin AJ, Radulovic S, Conley FK, Johnson DL, Schally AV ANTI CANCER DRUGS 1992 3 5 519-523
126. Human pancreatic cancer cell lines do not express receptors for somatostatin. Gillespie J, Poston GJ, Schachter M, Guillou PJ BR J CANCER 1992 66 3 483-487
127. Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Szende B, Juhasz E, Lapis K, Schally AV UROL RES 1992 20 6 383-386
128. [The analgesic and antiinflammatory activity of vapreotide, a somatostatin analog, in the polyarthritic rat]. Activité analgesique et anti-inflammatoire du vapreotide, analogue de la somatostatine, chez le rat polyarthritique. Betoin F, Duchene-Marullaz P, Lavarenne J, Eschalier A DOULEUR ANALG 1992 5 4 145
129. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. Logothetis C, Hoosein N J CELL BIOCHEM 1992 50 Suppl H 128-134
130. Preliminary clinical evidence for analgesic effect of vapreotide [letter]. Aumaitre O, Marcheix JC, Fialip J, Eschalier A, Duchene-Marullaz P, Dordain G DICP ANN PHARMACOTHER 1991 25 10 1136-1137
131. effects of epidermal growth factor and analogues of lhrh and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Lee MT, Liebow C, Kamer AR, Schally AV PROC NATL ACAD SCI U S A 1991 885 1656-1660
132. Effects of somatostatin-14 and its analogs on the calcium magnesium ATPase in the rat anterior pituitary. Miller GV, Primrose JN GUT 1991 32 10 A1244
133. Influence of growth factors on growth of pancreatic cancer in vitro. Kapur D, Davies NM, Gillespie J, Schially AV, Guillou PJ, Poston GJ GUT 1991 32 10 A1243
134. Vapreotide, BMY-41606, RC-160. DRUGS FUTURE 1991 16 11 1075
135. Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats. Qin Y, Schally AV, Willems G INT J CANCER 1991 47 5 765-770
136. In-vitro growth inhibitory effects of somatostatin analogs on human gastric carcinoma. Miller GV, Primrose JN GASTROENTEROLOGY 1991 100 5 PART 2 Abs 655
137. Growth inhibition of colon cancer with somatostatin analogue RC-160 in rats. Oin Y, Schally AV, Willems G GASTROENTEROLOGY 1991 100 5 PART 2 Abs 392
138. Efficacy and tolerance of somatostatin analogue RC-160 in a phase 1B study in pancreatic cancer. Poston GJ, Schally AV, Comaru-Schally AM, Grandjean E, Guillou PJ GASTROENTEROLOGY 1991 100 5 Part 2 Abs 295
139. Inhibitory effect of somatostatin analog RC-160 on EGF and TGF-alpha stimulated pancreatic cancer growth in vivo. Poston GJ, Japur P, Davies N, Gillespie J, Schally AV, Guillou PJ GASTROENTEROLOGY 1991 100 5 Part 2 A295
140. Long-lasting antinociceptive effect of RC-160, a somatostatin analog, in mice and rats. Eschalier A, Aumaitre O, Ardid D, Fialip J, Duchene-Marullaz P EUR J PHARMACOL 1991 199 1 119-121
141. Inhibitory effect of somatostatin analogue RC-160 on EGF and transforming growth factor alpha TGF-A stimulated pancreatic cancer growth in-vivo Davies NM, Kapur P, Gillespie J, Schally AV, Guillou PJ, Poston GJ BR J CANCER 1991 64 Suppl 154
142. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Szende B, Srkalovic G, Schally AV, Lapis K, Groot K CANCER 1990 65 10 2279-2290
143. RC-160 DRUGS FUTURE 1990 15 11 1144
144. Central long-lasting analgesic effect of RC_160, an analog of somatostatin Eschalier A, Ardid D, Aumaitre O, Fialip J, Duchene-Marullaz P EUR J PHARMACOL 1990 183 3 1067
145. Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studies. Schally AV, Srkalovic G, Szende B, Redding TW, Janaky T, Juhasz A, Korkut E, Cai R. Z, Szepeshazi K, Radulovic S, Bokser L, Groot K, Serfozo P, Comaru SCHALLYAM J STEROID BIOCHEM MOL BIOL 1990 37 6 1061-1067
146. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV PROC SOC EXP BIOL MED 1990 193 3 209-218
147. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Zalatnai A, Schally AV CANCER RES 1989 49 7 1810-1815
148. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Szende B, Lapis K, Redding TW, Srkalovic G, Schally AV BREAST CANCER RES TREAT 1989 14 3 307-314
149. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Srkalovic G, Szende B, Redding TW, Groot K, Schally AV PROC SOC EXP BIOL MED 1989 192 3 209-218
150. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement. Zalatnai A, Schally AV INT J PANCREATOL 1989 4 2 149-160
151. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer Fekete M, Zalatnai A, Schally AV CANCER LETT 1989 45 2 87-91
152. Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture. Aguila MC, Rodriguez AM, Aguila Mansilla HN, Lee WT ENDOCRINOLOGY 1996 137 5 1585-1590
153. Vapreotide, Octastatin™. DRUGS FUTURE 1996 21 11 1205-1206
154. [Somatostatin and its analogs in the treatment of tumors]. Somatostatin und seine Analoga in der Behandlung von Tumorerkrankungen. Kath R, Keil I, Haus U, Farber L, Hoffken K ONKOLOGE 1996 2 5 483-490
155. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Zamora PO, Gulhke S, Bender H, diekmann D, Rhodes BA, Biersack H. J, Knapp FF INT J CANCER 1996 65 2 214-220
156. Molecular mechanisms of antiproliferative effect of somatostatin: Involvement of a tyrosine phosphatase. Lopez F, Esteve JP, Buscail L, Delesque N, Saint Laurent N, Vaysse N, Susini C METABOLISM 1996 45 8 Suppl 14-16
157. Comparison between activation of omithine decarboxylase and histidine decarboxylase in rat stomach. Ding XQ, Chen D, Rosengren E, Persson L, Hakanson R AM J PHYSIOL - GASTROINTEST LIVER PHYSIOL 1996 270 3 33-3 G476-G - 86
158. Vapreotide DRUGS FUTURE 1995 20 11 1210
159. 2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Perez J, Vezzani A, Civenni G, Tutka P, Rizzi M, Schupbach E., Hoyer D NEUROSCIENCE 1995 65 4 1087-1097
160. Radiolabelled peptides: Now and the future. Thakur ML NUCL MED COMMUN 1995 16 9 724-732
161. Can systematic research of hormone and growth factor receptors contribute to the recognition of acute and chronic types of breast cancer, of their specific mammary dysplasias, and of specific treatments?. Mathe G BIOMED PHARMACOTHER 1995 49 9 385-388
162. The clinical significance of somatostatin receptor expression in human breast cancer. Bootsma AH, Van EIJCKCHJ, Hofland LJ, Lamberts SWJ ENDOCR-RELAT CANCER 1995 2 4 281-292
163. Therapy of anorexia nervosa with somatostatin. Faltus F, Krch FD HOMEOST HEALTH DIS 1995 36 4 237-238
164. Characterization and distribution of somatostatin SS-1 and SRIF-1 binding sites in rat brain: Identity with SSTR-2 receptors. Schoeffter P, Perez J, Langenegger D, Schupbach E, Bobimac I, Lubbert H, Bruns C, Hoyer D EUR J PHARMACOL MOL PHARMACOL 1995 289 1 163-173
165. Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors. Hoyer D, Perez J, Schoeffter P, Langenegger D, Schupbach E,
166. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis. Crean DH, Liebow C, Lee M. T, Kamer AR, Schally AV, Mang TS J CANCER RES CLIN ONCOL 1995 121 3 141-149
167. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Robertson JFR, Watson SA, Hardcastle JD INT J CANCER 1995 63 1 69-75
168. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Rosenberg L, Barkun AN, Denis MH, Pollak M CANCER 1995 75 1 23-28
169. [Pancreatic cancer as a hormone responsive tumor]. A HASNYALMIRIGYRAK HORMONALIS BEFOLYASOLASANAK LETHETOSEGEI. Zalatnai A ORVOSKEPZES 1995 70 3 12-19
170. Expression of somatostatin receptor genes and their role in inhibiting Cl- secretion in HT-29cl.19A colonocytes. Warhurst G, Barbezat GO, Higgs NB, Reyl DESMARSF, Lewin MJM, Coy DH, Ross I, Grigor MR AM J PHYSIOL - GASTROINTEST LIVER PHYSIOL 1995 269 5 32-5 G729-G - 36
171. 1H NMR and computer modeling conformational analysis. Varnum JM, Thakur ML, Schally AV, Jansen S, Mayo KH J BIOL CHEM 1994 269 17 12583-12588
172. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Buscail L, Delesque N, Esteve J. P, Saint LAURENTN, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C PROC NATL ACAD SCI U S A 1994 91 6 2315-2319
173. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y J CLIN INVEST 1994 93 3 1321-1325
174. Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity. Sirianni MC, Annibale B, Fais S, Delle FAVEG PEPTIDES 1994 15 6 1033-1036
175. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yang T ACTA ONCOL 1994 33 6 693-701
176. Tc-99m labeled somatostatin analogue, RC-160: 1H-NMR and computer modeling conformational analysis. Vamum JM, Mayo KH, Schally AV, Thakur ML J LABEL COMPD RADIOPHARM 1994 35 - 549-551
177. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Oberg K, Eriksson B, Janson ET ANN NY ACAD SCI 1994 733 - 471-478
178. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28. Panetta R, Greenwood MT, Warszynska A, Demchyshyn LL, Day R, Niznik HB, Srikant CB, Patel YC MOL PHARMACOL 1994 45 3 417-427
179. Management of bowel obstruction in advanced cancer. Ripamonti C CURR OPIN ONCOL 1994 6 4 351-357
180. Treatment of neuroendocrine tumors. Oberg K CANCER TREAT REV 1994 20 4 331-355
181. A new radiolabelled somatostatin analogue [111 In-DTPA-D-Phe1]RC-160: Preparation, biological activity, receptor scintigraphy in rats and comparison with [111 In-DTPA-D-Phe1]octreotide. Breeman WAP, Hofland LJ, Van Der Pluij MM, Van Koetsveld PM, De Jong M, Setyono Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SWJ, Krenning EP EUR J NUCL MED 1994 21 4 328-335
182. Combined hormonal therapy and chemotherapy for pancreatic cancer: Use of cytotoxic peptide analogs for targeted chemotherapy. Schally AV, Nagy A, Cai RZ, Reile H, Radulovic S, Qin Y, Szepeshazi K, Halmos G, Comaru SCHALLYAM INT J PANCREATOL 1994 16 2-3 277-280
183. Regulation of kinases and phosphatases during carcinogenesis. Liebow C INT J PANCREATOL 1994 16 2-3 271-274
184. Paraneoplastic syndromes. Eckhardt SJ CANCER SURV 1994 21 - 197-209
185. Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier. Banks WA, Kastin AJ, Sam HM, Cao VT, King B, Maness LM, Schally AV BRAIN RES BULL 1994 35 2 179-182
186. Molecular pharmacology of somatostatin-receptor subtypes. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H ANN NY ACAD SCI 1994 733 - 138-146
187. Brain-to-blood transport of peptides and the alcohol withdrawal syndrome. Banks WA, Kastin AJ ANN NY ACAD SCI 1994 739 - 108-118
188. The effect of somatostatin on cellular proliferation. Yamada T, Creutzfeldt W, Beglinger C, Chiba T GASTROENTEROL INT 1994 7 1 13-23
189. Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A J PHARMACOL EXP THER 1994 269 1 7-14
190. Somatostatin binding in human gastrointestinal tissues: Effect of cations and somatostatin analogues. Miller GV, Preston SR, Woodhouse LF, Farmery SM, Primrose JN GUT 1993 34 10 1351-1356
191. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. Hoosein NM, Logothetis CJ, Chung LWK J UROL 1993 149 5 1209-1213
192. Vapreotide. DRUGS FUTURE 1993 18 11 1096-1097
193. 123I-Tyr3]octreotide. Breeman WAP, Hofland LJ, Bakker WH, Van Der Pluij MM, Van Koetsveld PM, De Jong M, Setyono Han B, Kwekkeboom DJ, Visser TJ, Lamberts SWJ, Krenning EP EUR J NUCL MED 1993 20 11 1089-1094
194. Somatostatin analogs for diagnosis and treatment of cancer. Weckbecker G, Raulf F, Stolz B, Bruns C PHARMACOL THER 1993 60 2 245-264
195. Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer [see comments]. Stiefel F, Morant R SUPPORTIVE CARE CANCER 19931 1 57-58
196. Preliminary results of RC-160 in patients with AIDS related diarrhea. Goldschmidt E, Gastiaburu J, Nephtel F, Girard PM, Vittecocq D, Comaru-Schally A, Schally AV J CANCER RES CLIN ONCOL 1990 116 Suppl PART 1 637
197. The in vitro growth inhibition of human prostate cancer cell lines DU-145 PC-3 by somatostatin analog RC-160. Taneja S, Kozlowski JM, Sherwood ER, Lee C, Grayhack JT J UROL 1990 143 4 Suppl 225A
198. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Poston GJ, Davies N, Schally AV, Schally AM, Gastiaburu J, Guillop PJ DIGESTION 1990 46 3 170
199. Phase one B study of somatostatin analogue RC-160 in the treatment of patients with advanced exocrine pancreatic cancer. Liebow C, Lee MT, Schally A METABOLISM 1990 39 9 Suppl 2 163-166
200. RC-160 an analog of somatostatin induces a long-lasting analgesic effect in animals. Ardid D, Aumaitre O, Fialip J, Eschalier A, Duchene-Marullaz P THERAPIE 1990 45
201. Dose-effect finding studies on endocrine parameters and tumor growth by the somatostatin analog RC-160 in rat pancreatic tumors. Klijn JGM, Setyono-Han B, Bakker GH, Foekens JA INVEST NEW DRUGS 1989 7 4 409
202. Scintigraphic behavior and therapy dose estimates from loco-regionally applied Re-188 somatostatin analog RC160. Bender H, Zamora PO, Biersack HJ J NUCL MED 1995 36 5 Suppl 83P-184P
203. Expression of SST2 somatostatin receptor subtype inhibited pancreatic tumor cell growth. Delesque N, Rauly I, Buscail L, Esteve JP, Schally AV, Vaysse N, Susini C GENE THER 1995 2 Suppl 1 S23
204. Efficacy of vapreotide (Octastatin, RC 160) in AIDS related diarrhea: A multicenter randomized open study. Benhamou Y, Bouchand O, Coulaud P, Dohin E, Katlama C, Dupont R, Coulaud JP, Gentilini M, Opolon P GASTROENTEROLOGY 1994 106 4 Suppl A651
205. Anticonvulsant effect of RC 160 and differential changes in hippocampal somatostatin receptors mRNA, binding sites and release in kainic acid (KA) treated rats. Vezzani A, Perez J, Rizzi M, Monno A, Tutka P, Schupbach E, Hoyer D SOC NEUROSCI ABSTR 1994 20 1-2 407
206. Effects of analogues of LH-RH and somatostatin on IGF-1 or EGF induced proliferation of endometrial cancer cells. Emons G, Stuckrad BV, Schulz KD, Schally AV J CANCER RES CLIN ONCOL 1994 120 Suppl R150
207. Tyrosine kinase promoting activity of analogues of somatostatin (SS) and LHRH. Liebow C, Lee MT, Karner AR, Schally AV PROCAM ASSOC CANCER RES 1993 34 412
208. Somatostatin analogue RC-160 eliminates premalignant lesions induced in the hamster buccal cheek pouch by DMBA. Karner AR, Liebow C, Crean DH, Mang TS, Szepeshazi K, Bradford P, Schally AV PROC AM ASSOC CANCER RES 1993 34 293
209. Debiopharm: Products. Debiopharm SA COMPANY WORLD WIDE WEB SITE 2000 February 07
210. Anti-nociceptive effect induced by somatostatin released from sensory nerve terminals and by synthetic somatostatin analogues in the rat. Helyes Z, Than M, Oroszi G, Pinter E, Nemeth J, Keri G, Szolcsanyi J NEUROSCI LETT 2000 278 3 185-188
211. Neuroendocrine tumours of the pancreas. Eriksson B, Oberg K BR J SURG 2000 87 2 129-131
212. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. Dasgupta P, Mukherjee R BR J PHARMACOL 2000 129 1 101-109
213. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Smith Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangert T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Kofler A, Schlangbauer-Wadl H, Traub T, Virgolini I ENDOCRINOLOGY 1999 140 11 5136-5148
214. Somatostatin analogs stimulate DNA-dependent protein kinase activity in human gastric tumoral cell-tine HGT1. Sadji Z, Le Romancer M, Hervatin F, Lewin MJ, Reyl Desmars F LIFE SCI 1999 65 26 2829-2835
215. Two methods to encapsulate a somatostatin analogue into PLGA microspheres. Blanco Prieto MJ, Besseghir K, Orsolini P, Heimgartner F, Merkle HP, Gander B PROC CONTROL RELEASE SOC 1999 - 26 1076-1077
216. Neuroendocrine cells in tumour growth of the prostate. Abrahamsson PA ENDOCR-RELAT CANCER 1999 6 4 503-519
217. [Expression of somatostatin receptors: Therapeutic considerations]. Expression des recepteurs de la somatostatine: Considerations therapeutiques. Weckbecker G ANN ENDOCRINOL 1998 59 Suppl 2 6-7
218. Stability of Octastatin, a somatostatin analog cyclic octapeptide, in aqueous solution. Jang SW, Woo BH, Lee JT, Moon SC, Lee KC, DeLuca PP PHARM DEV TECHNOL 1997 2 4 409-414
219. First disposable micropump for peptide delivery. Saaman A, Aubert C, Neftel F PROC CONTR RELEASE SOC 1994 - 21 359-360
220. Drug development pipeline: vapreotide. Debiopharm SA COMPANY COMMUNICATION 2000 April 10
221. Fluorine-18 labeled vapreotide (F-18-RC160) a somatostatin analog: a potential radiopharmaceutical for cancer detection by PET imaging. Amartey JK, Jammaz I, Parhar RS, Mohanna F PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 4503
222. Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology - Third World Meeting (Part II), Pharmaceutical Biotechnology, Microparticles, Emulsions and Pharmaceutical Packaging, Berlin, Germany. Kas HS IDDB MEETING REPORT 2000 April 3-6
223. Summary of the American Association for Cancer Research 91st Annual Meeting, San Francisco, CA, USA. Worker C, Brown H IDDB MEETING REPORT 2000 April 1-5
224. Transcriptional activation of mouse SST2 somatostatin receptor promoter by transforming growth factor B: Involvement of SMAD4 Puente E, Saint-Laurent N, Furet C, Torrisani J, Vaysse N, Buscail L, Susini C GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 1700
225. Vapreotide, a long-acting somatostatin analogue, dose-dependently inhibits exocrine pancreatic secretion in healthy volunteers. Hildebrand Pius, Nair G, Ketterer S, Beglinger C, Aeschlimann CA, Dumont JM, Besseghir K GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 2149
226. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Szende B, Zalatnai A, Schally AV PROC NATL ACAD SCI U S A 1989 86 5 1643-1647
227. Membrane receptors for peptides in experimental and human pancreatic cancers. Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV PANCREAS 1989 4 5 521-528
228. 2 and decreases elevated prolactin levels in rats. Bokser L, Schally AV ENDOCRINOLOGY 1988 123 4 1735-1739
229. Summary of Digestive Disease Week 2000 San Diego, CA, USA Hilton J IDDB MEETING REPORT 2000 May 21-24
230. Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats. Karashima T, Schally AV PEPTIDES 1988 9 3 561-565
231. Biologically active lysine-containing octapepttdes. Schally AV, Cal RZ EUROPEAN PATENT 1986 EP-00203031
232. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, Prasad PN, Liebow C CANCER RES 2000 60 15 4194 -4199
233. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Froidevaux S, Heppeler A, Eberle AN, Meier AM, Hausler M, Beglinger C, Behe M, Powell P, Macke HR ENDOCRINOLOGY 2000 141 9 3304-3312
234. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A J CLIN ENDOCRINOL METAB 2000 85 7 2564-2571
235. Template-constrained cyclic peptide analogues of somatostatin: Subtype-selective binding to somatostatin receptors and antiangiogenic activity. Suich DJ, Mousa SA, Singh G, Liapakis G, Reisine T, DeGrado WF BIOORG MED CHEM 2000 8 9 2229-2241
236. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its anti-proliferative activity on human oral carcinoma cells in vitro. Dasgupta P, Singh AT, Mukherjee R LIFE SCI 2000 66 17 1557-1570
237. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst5 receptor. Feuerbach D, Fehlmann D, Nunn C, Siehler S, Langenegger D, Bouhelal R, Seuwen K, Hoyer D NEUROPHARMACOLOGY 2000 39 8 1451-1462
238. Pancreatic cancer: A review of emerging therapies. Rosenberg L DRUGS 2000 59 5 1071-1089
239. Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors. Vezzani A, Rizzi M, Conti M, Samanin R J NUTR 2000 130 4S Suppl 1046S-1048S
240. Receptor targeting for tumor localisation and therapy with radiopeptides. Heppeler A, Froidevaux S, Eberle AN, Maecke HR CURR MED CHEM 2000 7 9 971-994
241. Spleno-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats. Veal N, Oberti F, Moal F, Vuillemin E, Fort J, Kaassis M, Pilette C, Cal'es P J HEPATOL 2000 32 3 434-440
242. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR EUR J NUCL MED 2000 27 3 273-282
243. Formation of peptide impurities in polyester matrices during implant manufacturing. Rothen einhold A, Oudry N, Schwach Abdellaoui K, Frutiger Hughes S, Hughes GJ, Jeannerat D, Burger U, Besseghir K, Gurny R EUR J PHARM BIOPHARM 2000 49 3 253-257
244. Pharmacotherapy or surgery as primary treatment for acromegaly? Ferone D, Colao A, Van der Lely AJ, Lamberts SWJ DRUGS AGING 2000 17 2 81-92
245. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres. Blanco Prieto MJ, Besseghir K, Zerbe O, Andris D, Orsolini P, Heimgartner F, Merkle HP, Gander B J CONTROL RELEASE 2000 67 1 19-28
246. [Diagnosis of neuroendocrine tumors]. LA diagnostics dei tumori neuroendocrini. Chiti A, Bombardieri E TUMORI 2000 862 Suppl S9-S11
247. State of the art and future prospects in the management of neuroendocrine tumors. Oberg K QUART J NUCL MED 2000 44 1 3-12
248. Advances in understanding neuronal somatostatin receptors. Selmer IS, Schindler M, Allen JP, Humphrey PPA, Emson PC REGUL PEPT 2000 90 1-3 1-18
249. The integrity of the disulfide bond in a cyclic somatostatin analog during 99mTc complexation reactions. Uehara T, Arano Y, Ono M, Fujioka Y, Ogawa K, Namba S, Nakayama M, Koizumi M, Fujii N, Horiuchi K, Yokoyama A, Saji H NUCL MED BIOL 1999 26 8 883-890